PharmacoEconomics - Modern pharmacoeconomics and pharmacoepidemiology (E-Journal) / ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология
Not a member yet
430 research outputs found
Sort by
Клинико-экономическая оценка эффективности и безопасности существующей практики проведения периоперационной антибиотикопрофилактики на оcнове фармакоэпидемиологического исследования в многопрофильных стационарах Санкт-Петербурга
Get PDFA survey conducted in four hospitals located in the city of St. Petersburg revealed that the commonly used perioperative antibiotic prophylaxis (PAP) did not follow (in 88% of cases) the guidelines approved for national clinical practice.Aim. To perform a cost-effectiveness analysis of the commonly practiced PAP among patients with clean, clean-contaminated and contaminated surgical wounds in a multidisciplinary hospital.Materials and methods. The PAP cost-effectiveness analysis was performed using the data from a multicenter epidemiological survey and previously conducted studies. The Markov model was used to compare the effectiveness and safety of the commonly used PAP with that recommended by the clinical practice guidelines. The rate of surgical site infection (SSI) and antibiotic-associated diarrhea (AAD) were chosen for the endpoints.Results. The costs associated with a single case of PAP according to the clinical practice guidelines was 3.5 times less than that associated with the PAP used in the common practice (RUB 4913,67 and 17837,71 respectively). The present analysis demonstrates that the PAP recommended by the clinical practice guidelines was more cost-effective as compared with the commonly practiced PAP.Conclusion. Regular epidemiological monitoring is required to improve effectiveness and safety of the existing PAP practice.
Особенности симуляционного моделирования при оценке клинико-экономических исходов сахарного диабета 1-го и 2-го типов
Get PDFThe process of decision modelling in diabetes mellitus (DM) is often complicated by comorbidity among diabetic patients, complexity of endpoint selection, and unclear time horizons. Aim. To review the available recommendations, relevant methods and mathematical approaches to decision modelling in DM. Materials and Methods. We searched through the PubMed database using the ResearchGate and Mendeley networks; we also collected data from the websites of the key opinion leaders in the field of pharmacoeconomics and decision modelling. Results. This review contains up-to-date information on the validity of the most common DM decision models and on the validity of extrapolating the type 2 DM models to patients with type 1 DM. We also provide some clinically relevant comments on the American Diabetes Association’s requirements concerning the decision models in DM. The review incorporates data on the current mathematical approaches to modelling the changes in glycated hemoglobin levels, the body mass index and the quality-adjusted life expectancy – for both type 1 and type 2 DM. Conclusion. Despite recent successes in DM decision modelling, the existing approaches are not always relevant to some groups of DM patients or to some aspects of the disease. Thus, the use of the novel anti-diabetic drugs (liraglutide, semaglutide, empagliflozin) capable of significantly reducing cardiovascular risks in DM patients, require new approaches to decision modelling in diabetes mellitus.
Фармакоэкономический анализ применения комбинации олмесартан/лерканидипин и зофеноприл/лерканидипин в лечении пациентов с гипертонической болезнью
Get PDFObjective. Pharmacoeconomic analysis of the use of combinations of antihypertensive drugs were olmesartan/lercanidipine and zofenopril/lercanidipine in patients with essential hypertension II-III stage.Materials and methods. The authors performed prospective randomized uncontrolled study. Were examined in 27 people essential hypertension with II-III stage age from 40 to 71 years before and after the use of combinations of drugs olmesartan/lercanidipine and zofenopril/lercanidipine. An ABC/VEN-analysis, сost-effectiveness analysis, comparative assessment of the incidence of side effects of the studied drugs were performed.Results. Anti-hypertensive effect of the studied combinations of drugs were not significantly different and equally effectively reduced blood pressure. But the cost of blood pressure reduction at 1 mm Hg was the smallest in the group zofenopril/lercanidipine.Conclusion. The results of pharmacoeconomic analysis to be more cost-effective combination for the treatment of patients with essential hypertension II-III stage is the combination of zofenopril/lercanidipine.Цель – фармакоэкономический анализ применения комбинаций антигипертензивных препаратов олмесартан/лерканидипин и зофеноприл/лерканидипин у пациентов с гипертонической болезнью (ГБ) II-III стадии.Материалы и методы. Проведено проспективное рандомизированное неконтролируемое исследование. бследовано 27 человек с ГБ II-III стадии в возрасте от 40 до 71 года до и после применения комбинаций препаратов олмесартан/лерканидипин и зофеноприл/лерканидипин. Проведен ABC/VEN-анализ, анализ «затраты-эффективность», сравнительная оценка частоты побочных эффектов исследуемых препаратов.Результаты. По антигипертензивному эффекту исследуемые комбинации препаратов существенно не отличались и одинаково эффективно снижали уровень АД. Но стоимость снижения АД на 1 мм рт. ст. была наименьшей в группе зофеноприл/лерканидипин.Заключение. По результатам фармакоэкономического анализа наиболее экономически выгодной комбинацией для лечения пациентов с ГБ II-II стадии является комбинация зофеноприл/лерканидипин
Затраты на регионарную анестезию с применением левобупивакаина, рацемического бупивакаина и ропивакаина
Get PDFФАРМАКОЭКОНОМИЧЕСКИЙ АНАЛИЗ ЭФФЕКТИВНОСТИ ПЕРАМПАНЕЛА ПРИ ЛЕЧЕНИИ РЕФРАКТЕРНОЙ ПАРЦИАЛЬНОЙ ЭПИЛЕПСИИ СО ВТОРИЧНОЙ ГЕНЕРАЛИЗАЦИЕЙ И БЕЗ НЕЕ В УСЛОВИЯХ ЗДРАВООХРАНЕНИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ
Get PDFPerampanel (PER) is a novel drug for treatment of refractory partial epilepsy in patients≥12 y.o. with proven efficacy and safety. PER is registered and may also be used successfully as adjunctive treatment in therapy of primary generalized tonic-clonic seizures (PGTCS).Objective. To determine the effectiveness of perampanel and it`s clinical stability in patients at different dosing regimens, and evaluate the cost of treatment with perampanel in the Russian Health Care system.Materials and Methods. Results of open multicenter controlled randomized (phase III) international clinical trials in patients over 12 years of age were used. Modeling of the direct costs was based on (i) the probable treatment outcomes: i.e., no clinical effect, treatment cessation due to adverse events, seizures reduction of 50% and more, complete seizure termination, (ii) the expected number of the above outcomes all overRussia, and (iii) the inflation risks in the period until 2020.Results. The comparison of different clinical studies on adjunctive perampanel therapy in refractery partial epilepsy with or without secondary generalization as well as in primary generalized tonic-clonic seizures, reveales that the optimal daily dose of perampanel is 8 mg.Conclusion. Direct costs modeling was performed to estimate annual expenses (per patient) of the adjunctive perampanel therapy. When recalculated for all patients with refractory partial epilepsy and for all patients with PGTCS inRussia, the results indicate that the introduction of perampanel may reduce the costs by more than 40% (up to 4-7 bln. rubles) annually until 2020.
ФАРМАКОЭКОНОМИЧЕСКИЙ АНАЛИЗ ПРИМЕНЕНИЯ БРЕНТУКСИМАБА ВЕДОТИНА В ТЕРАПИИ РЕЦИДИВИРУЮЩЕЙ ИЛИ РЕФРАКТЕРНОЙ CD30+ СИСТЕМНОЙ АНАПЛАСТИЧЕСКОЙ КРУПНОКЛЕТОЧНОЙ ЛИМФОМЫ У ПАЦИЕНТОВ СТАРШЕ 18 ЛЕТ: РЕЗУЛЬТАТЫ АНАЛИЗА ВЛИЯНИЯ НА БЮДЖЕТ ЗДРАВООХРАНЕНИЯ
Get PDFObjectives. To provide a pharmacoeconomic analysis of brentuximab vetodin therapy in relapsed or refractory CD30+ systemic anaplastic large-cell lymphoma in patients over 18 years of age.Methods. Recommendations to carry out a budget impact analysis in theRussian Federation (2016) were used.Results. The analysis covered a period of 3 years. The target population of patients with relapsed or refractory CD30+ systemic anaplastic large cell lymphoma numbered 345 individuals. The results indicate that the introduction of brentuximab vetodin in the List of vital and essential drugs and the Program of state-guaranteed free medical care will not increase the costs of the treatment in patients with relapsed or refractory CD30+ systemic anaplastic large cell lymphoma.Conclusion. The brentuximab vetodin therapy of relapsed or refractory CD30+ systemic anaplastic large cell lymphoma is an economically reasonable and resource-saving medical modality. Цель – оценить расходы здравоохранения на применение брентуксимаба ведотина в терапии рецидивирующей или рефрактерной CD30+ системной анапластической крупноклеточной лимфомы (cАККЛ) у пациентов старше 18 лет.Материалы и методы. Использовали российские рекомендации проведения анализа влияния на бюджет (2016 г.).Результаты. Временной горизонт анализа составил 3 года. Численность целевой популяции была представлена в размере 345 пациентов с рецидивирующей или рефрактерной сАККЛ. Показано, что включение препарата брентуксимаб ведотин в Перечень жизненно необходимых и важнейших лекарственных препаратов (ЖВНЛП) и Программу государственных гарантий бесплатного оказания гражданам медицинской помощи не приведет к увеличению затрат здравоохранения на лекарственное обеспечение пациентов с рецидивирующей или рефрактерной сАККЛ.Заключение. Терапия рецидивирующей или рефрактерной сАККЛ препаратом брентуксимаб ведотин является экономически целесообразной и ресурсосберегающей медицинской технологией.
Фармакоэкономическая оценка применения помалидомида (Имновид) для лечения больных с рецидивирующей и рефрактерной множественной миеломой
Get PDFThe aim of the study is to assess the economic feasibility of using pomalidomide in patients with recurrent and refractory multiple myeloma (MM), who had received previous 1st and 2nd (bortezomib and lenalidomide) line therapy.Materials and Methods. In this study, the methods of cost analysis, cost – effectiveness analysis, budget impact analysis (in relation to the State Guarantees Program) as well as sensitivity-toprice-change analysis were used.Results. The results indicate that the pomalidomide therapy in patients with recurrent and refractory MM who had previously received 1st and 2nd (bortezomib and lenalidomide) line therapy is clinically beneficial and also economically feasible in terms of public procurement. If introduced this program can save the Federal budget up to 232 785 963 rubles.Conclusion. According to the budget impact analysis, if pomalidomide (Innovid) is included in the list of public procurement, then the Federal spending on the treatment of MM with pomalidomide, lenalidomide and bortezomib will be less by 12% compared to the MM treatment with bortezomib and lenalidomide only
